What insurance policy changes affect code R20.2?

There are 4 tracked policy changes affecting code R20.2, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code R20.2?

Payers that have issued tracked updates for code R20.2 include: Aetna.

How do I get notified when code R20.2 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code R20.2. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code R20.2?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

R20.2 Insurance Policy Changes

ICD-10 R20.2 is officially defined as "Paresthesia of skin." code R20.2 is referenced in 4 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R20.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 15, 2026Medium impact
Cerebral Perfusion Studies (CPB 0663, reviewed 2026-04-14)
Aetna considers CT perfusion studies of the brain medically necessary for evaluating acute stroke (less than 24 hours), including hemorrhagic stroke, subdural hemorrhage and transient ischemic attacks, for following up cerebral ischemia or infarction, for planning therapy for cervical or intracranial arterial occlusive disease, for identifying cerebral hyperperfusion after revascularization, and for evaluating the vascular status of solid tumors when MRI is degraded by susceptibility artifact. Aetna considers MRI perfusion studies medically necessary for diagnosing and following mass lesions such as glioma, for assessing acute stroke penumbra, and for assessing the hemodynamic significance of cervical or intracranial vascular stenosis and the efficacy of revascularization. Aetna considers CT perfusion experimental, investigational or unproven for indications including confirmation of brain death, differentiation of lung cancer from benign lesions, evaluation of head trauma and evaluation of cerebral vasospasm, and considers MRI perfusion unproven for indications including evaluation of traumatic brain injury, evaluation of persistent pain and prognostication of obstructive sleep apnea.
Aetna · Identified Aug 14, 2026Medium impact
Pudendal Nerve Decompression (CPB 0805, reviewed 2025-11-20)
Aetna clinical policy bulletin 0805 considers pudendal nerve decompression experimental, investigational, or unproven for indications including chronic pelvic pain, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder, pudendal neuralgia, and vulvodynia. The policy also considers pudendal nerve hydrodissection for chronic pelvic pain syndrome and urinary incontinence, and pudendal neurolysis for persistent genital arousal disorder and pudendal nerve entrapment syndrome, experimental, investigational, or unproven. The policy does not apply to pudendal nerve blocks used in obstetrics and other operative procedures.
Aetna · Identified Aug 12, 2026Medium impact
Orthognathic Surgery (CPB 0095, reviewed 2026-03-18)
Aetna considers orthognathic surgery medically necessary for correction of maxillary or mandibular skeletal deformities that contribute to significant masticatory dysfunction, to airway dysfunction, or to obstructive sleep apnea, when dental therapeutics and orthodontics alone cannot adequately treat them, and for speech impairments accompanying severe cleft deformity. Orthognathic surgery performed primarily for cosmetic purposes is not covered, and no benefits are available for it. Orthognathic surgery for temporomandibular joint disease is considered experimental, investigational, or unproven, and so are several listed techniques such as Kinesio taping and three-dimensional virtual treatment planning.
Aetna · Identified Nov 2, 2026Low impact
Pudendal Nerve Decompression (CPB 0805, reviewed 2026-10-28)
Aetna's clinical policy bulletin 0805 on pudendal nerve decompression was reviewed on 10/28/2026. It treats pudendal nerve decompression, hydrodissection and neurolysis as experimental, investigational or unproven for chronic pelvic pain, pudendal neuralgia, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder and vulvodynia, and it lists three related CPT codes as not covered for those indications. The source does not state an effective date for a change or describe a coverage change in this review.

Watch R20.2

Get one email when a payer policy names R20.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Cerebral Perfusion Studies (CPB 0663, reviewed 2026-04-14)

Pudendal Nerve Decompression (CPB 0805, reviewed 2025-11-20)

Orthognathic Surgery (CPB 0095, reviewed 2026-03-18)

Pudendal Nerve Decompression (CPB 0805, reviewed 2026-10-28)

What insurance policy changes affect code R20.2?

Which payers have updated policy for code R20.2?

How do I get notified when code R20.2 policy changes?

Why do payers change policies for code R20.2?